Find policies, billing codes, payers, states, and providers
CPT 80307: Presumptive Instrumented Drug Screen
Headline: New Overview — CPT code 80307 for Instrumented Presumptive Drug Screening
Lead: CPT code 80307 designates a laboratory-performed presumptive drug test using instrumented chemistry analyzers to screen for multiple drug classes on a single date. The code captures a widely used screening method that supports clinical decision-making, substance use monitoring, and workplace or forensic testing pathways.
What the code represents and why it matters: CPT code 80307 identifies an automated, instrument-based toxicology screen that produces rapid qualitative results across drug classes. As presumptive testing is often the initial step before confirmatory assays, this code is central to workflows in emergency care, occupational health, behavioral health, and inpatient settings. Nationally, standardized coding of these screens affects billing consistency, utilization tracking, and laboratory service reporting.
Key payers included: This summary covers payer applicability for Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
What readers will learn: The publication presents benchmarks for utilization and reimbursement patterns, outlines common clinical contexts where 80307 is used, and summarizes relevant policy considerations affecting laboratory toxicology screening. It also highlights operational implications for laboratories and ordering clinicians, and notes where input data are not available. The focus is national in scope and designed for billing managers, laboratory directors, and policy analysts seeking a concise reference on CPT code 80307.
Customize your policy alerts
Sign up for cpt 80307 policy alerts
Get alerted when payer policies referencing 80307 are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 80307 describes a presumptive drug test performed by a laboratory analyst using instrumented chemistry analyzers to screen for any number of drug classes on a single date. This service is a laboratory-based toxicology screening that produces qualitative results indicating the presence or absence of target drug classes.
Service type: Laboratory toxicology screen (instrumented chemistry analyzer service)
Typical site of service: Clinical laboratory or hospital laboratory; testing may be ordered by outpatient clinics, emergency departments, inpatient services, or other clinical settings and performed in a certified laboratory.
National Reimbursement Benchmarks
National commercial reimbursement for CPT 80307 clusters around BUCA’s average commercial rate of $136.60, with substantial differences among individual payers. Blue Cross Blue Shield displays the highest mean and a high median near $195.10, while Aetna and Cigna both show means near $61–$63 and medians in the low $50s. UnitedHealth Group’s mean is lower at $51.20 with a median of $37.30. These differences indicate a stratified market where BUCA sits between the higher Blue Cross Blue Shield levels and the lower Aetna/Cigna/UnitedHealth Group segment.
Dispersion measured by the interquartile range (P75–P25) highlights variation in contract pricing: Blue Cross Blue Shield’s IQR is $109.50 (P75 $242.80 minus P25 $141.30), the widest, while UnitedHealth Group is the tightest with an IQR of $33.20 (P75 $62.10 minus P25 $26.90). Cigna and BUCA show moderate dispersion at $50.70 and $76.30 respectively, and Aetna’s IQR is $24.00, indicating relatively concentrated pricing for Aetna and UnitedHealth Group compared with Blue Cross Blue Shield.